PubFacts Top Author
As a PubFacts Top Author, your profile will be highlighted and featured at the top of your specialty category.
2,372 results match your criteria Canadian Urological Association Journal [Journal]
Can Urol Assoc J 2018 Jun;12(6Suppl2):S49-S50
Can Urol Assoc J 2018 Jun;12(6):173-180
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada.
Introduction: The Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use of target agents as adjuvant therapy in patients with non-metastatic renal cell carcinoma (nmRCC) after nephrectomy. We reviewed the published data and performed a meta-analysis of studies that focused on vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs).
Methods: A systematic literature search identified seven trials on adjuvant target therapy in nmRCC. Read More
Can Urol Assoc J 2018 Jun;12(6(Suppl3)):S147-S148
Division of Urology, University of Toronto, Toronto, ON.
Can Urol Assoc J 2018 Jun;12(6(Suppl3)):S145
Department of Urology, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S189-S190
Department of University, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S186-S188
Department of Urology, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S184-S185
Division of Urology, Toronto Western Hospital, University of Toronto, Toronto ON.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S181-S183
Department of Urology, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S178-S180
Department of Urology, Kingston Health Sciences Centre, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S175-S157
Departments of Psychology, Anesthesiology & Urology, Queen's University, Kingston ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S171-S174
Co-founder, Pelvic Health Solutions.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S167-S170
Division of Urology, Western University, London, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S164-S166
Division of Urology, University of Toronto, Toronto, ON.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S161-S163
Department of Urology, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S157-S160
Department of Urology, Dalhousie University, Halifax, NS, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S155-S156
Department of Anesthesia, University Health Network, University of Toronto, Toronto, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S152-S154
Department of Urology, Queen's University, Kingston, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6 Suppl 3):S149-S151
University of Toronto, Toronto, ON, Canada.
Can Urol Assoc J 2018 Jun;12(6):E269
Président de l'AUC.
Can Urol Assoc J 2018 Jun;12(6):187
Northern Alberta Urology Centre, Edmonton, AB, Canada.
Can Urol Assoc J 2018 Jun;12(6):153
CUA President.
Can Urol Assoc J 2018 Jun;12(6):151
CUAJ Associate Editor and Professor of Surgery (Urology), McMaster University, Hamilton, ON, Canada.
Can Urol Assoc J 2018 May 22;12(5):E197-E209. Epub 2018 Feb 22.
Department of Surgery, Division of Urology Western University, London, ON; Canada.
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Department of Surgery (Urology) and Oncology, McMaster University, Hamilton, ON; Canada.
Multiple new agents to treat metastatic castration-resistant prostate cancer (mCRPC) have become available in recent years; however, the appropriate timing and sequencing of these agents have yet to be elucidated. Until accurate biomarkers become available to allow more focused therapeutic targeting for this population, treatment selection for men with mCRPC will continue to be driven largely by close assessment of patient-related factors and symptoms. Pain, as the predominant symptom of mCRPC, is often the focus when assessing progression and the need for a change in treatment. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Istanbul Medeniyet University, Faculty of Medicine, Department of Pediatric Urology; Istanbul, Turkey.
Introduction: We sought to report the outcomes of transperitoneal laparoscopic heminephroureterectomy (LHNU) in pediatric population and to describe the technical details of this minimally invasive surgery.
Methods: Seventeen pediatric patients (18 renal units), who had consecutive transperitoneal LHNU in our department between January 2012 and July 2017 were included in the study. In all patients, diagnostic cystoscopy and retrograde pyelography were carried out immediately before the operation. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Urology Institute, University Hospitals Cleveland Medical Center.
Introduction: We sought to prospectively evaluate the effectiveness of the multidisciplinary tumour board (MTB) on altering treatment plans for genitourinary (GU) cancer patients.
Methods: All GU cancer patients seen at our tertiary care hospital are discussed at MTB. We prospectively collected data on adult patients discussed over a continuous, 20-month period. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States.
Introduction: We aimed to investigate patient and disease variables associated with gynecological organ invasion in females with bladder cancer at the time of robot-assisted radical cystectomy (RARC).
Methods: We conducted a retrospective review of female patients who underwent robot-assisted anterior pelvic exenteration (RAAE) between 2005 and 2016. Patients were divided into two groups: those with gynecological organ involvement at RAAE and those without. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Cleveland Clinic-Glickman Urological & Kidney Institute, Cleveland, OH, United States.
Introduction: We aimed to characterize current practice patterns among endourologists on medical expulsive therapy (MET) for treatment of ureteral calculi.
Methods: An online survey was administered to Endourological Society members. Respondents' MET usage, index case management, and awareness of recent guidelines and literature were compared based on international status, practice setting, interval since training, and endourological fellowship training. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Department of Surgery, Division of Urology, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada.
Introduction: We assessed the impact of targeted therapies on healthcare resource use and compared treatment regimens used in patients diagnosed with metastatic renal cell carcinoma (mRCC).
Methods: Clinicopathological and administrative data of patients with mRCC from our institution were retrospectively collected from January 2000 to August 2014. Patients were divided into two groups based on the use of targeted therapies. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Department of Urology, Jewish General Hospital, McGill University.
Introduction: Overactive bladder syndrome (OAB) is a highly prevalent and costly condition worldwide with negative impact on health-related quality of life. Although many guidelines exist and anticholinergics are considered to be the mainstay of pharmacological treatment, data are lacking regarding optimal treatment duration. Therefore, the aim of this study was to determine practice patterns of Canadian urologists and gynecologists regarding duration of OAB pharmacotherapy. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Schulich School of Medicine and Dentistry, Western University, London, ON.
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Department of Urology.
Introduction: Radical nephrectomy (RN) with venous tumour thrombectomy (VTT) carries a significant morbidity and mortality risk. Examination of a contemporary single-institution series permits the development of a management algorithm and an audit its results. We report outcomes following the use of intraoperative colour Doppler ultrasound and our surgical pathway. Read More
Can Urol Assoc J 2018 May 14. Epub 2018 May 14.
Department of Urological Sciences, Vancouver General Hospital.
Can Urol Assoc J 2018 04 12. Epub 2018 Apr 12.
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON.
Introduction: Treatment using abiraterone acetate, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improve overall survival (OS) and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada.
Methods: We describe provincial differences in access to approved mCRPC therapies. Read More
Can Urol Assoc J 2018 04 12. Epub 2018 Apr 12.
University of British Columbia, Vancouver, BC.
Introduction: Upper tract urothelial carcinoma (UTUC) accounts for 5% of all urothelial tumours. Due to its rarity, evidence regarding postoperative surveillance is lacking. The objective of this study was to develop a post-radical nephroureterectomy (RNU) surveillance protocol based on recurrence patterns in a large, multi-institutional cohort of patients. Read More
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S42-S47
Division of Urology, Department of Surgery, CHU de Québec, Université Laval, Quebec City, QC.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S37-S41
Department of Urology, Dalhousie University, Halifax, NS; Canada.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S34-S36
University of Saskatchewan, Saskatoon, SK; Canada.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S27-S33
Department of Surgery, Division of Urology, McMaster University, Hamilton, ON; Canada.
Hypospadias patients presenting to adult urologists do so with a wide range of symptoms and problems, including urethral stricture (45-72%), lower urinary tract symptoms (with or without stricture) (50-82%), urethrocutaneous fistula (16-30%), persisting hypospadias (14-43%), micturition spraying (24%), ventral curvature (14-24%), urinary tract infection (15-25%), or lichen sclerosus (13%; range 8-43). Many of these men have concurrent complications as the result of multiple operations and a variety of techniques. Patients with childhood repairs performed by a pediatric urologist are often lost to followup during adolescence and will reemerge in adulthood after what appeared to be a successful pediatric single-stage repair, stressing the need for long-term followup and transitional care. Read More
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S24-S26
Dalhousie University, Halifax, NS; Canada.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S15-S23
Division of Pediatric Urology, The Hospital for Sick Children, Toronto, ON; Canada.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S10-S14
Division of Urology, University of Western Ontario, London, ON; Canada.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S3-S9
Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB.
Can Urol Assoc J 2018 Apr;12(4 Suppl 1):S1
Department of Urology, Dalhousie University, Halifax, NS, Canada.
Can Urol Assoc J 2018 Apr 22;12(4):144. Epub 2017 Dec 22.
Président de l'AUC.
Can Urol Assoc J 2018 Apr 22;12(4):126. Epub 2017 Dec 22.
Urologic Oncology, Division of Urology, Ottawa Hospital Research Institute, The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada.
Can Urol Assoc J 2018 Apr 22;12(4):110-111. Epub 2017 Dec 22.
Department of Urologic Sciences, University of British Columbia, Vancouver, BC; Chair, CUA Health Policy Committee.
Can Urol Assoc J 2018 Apr 22;12(4):93-94. Epub 2017 Dec 22.
Minneapolis VA Medical Center, Minneapolis, MN, United States.
Can Urol Assoc J 2018 Apr 22;12(4):84. Epub 2017 Dec 22.
McGill University, Montreal, QC, Canada.